[DBVT] DBV Technologies S.A.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 1.5 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 35.08 Change: 0.35 (1.01%)
Ext. hours: Change: 0 (0%)

chart DBVT

Refresh chart

Strongest Trends Summary For DBVT

DBVT is in the long-term down -78% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding46 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow-57.9 ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week24.94 Low 52 week7.44 Last close9.69 Last change-3.2%
RSI47.61 Average true range0.44 Beta0.98 Volume41.07 K
Simple moving average 20 days0.05% Simple moving average 50 days4.51% Simple moving average 200 days-29.52%
Performance Data
Performance Week6.25% Performance Month-9.01% Performance Quart7.79% Performance Half-46.64%
Performance Year-56.45% Performance Year-to-date-41.38% Volatility daily3.02% Volatility weekly6.75%
Volatility monthly13.83% Volatility yearly47.9% Relative Volume364.91% Average Volume246.81 K
New High New Low

News

2020-05-12 16:01:00 | Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020

2020-04-30 16:01:00 | DBV Technologies Reports March 31, 2020 Cash Position

2020-04-20 16:01:00 | DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting

2020-04-15 06:00:00 | Monthly information regarding the total number of voting rights and total number of shares of the Company

2020-04-10 16:01:00 | Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

2020-03-31 03:46:16 | Analysts Just Made A Major Revision To Their DBV Technologies S.A. EPA:DBV Revenue Forecasts

2020-03-30 16:01:00 | Ordinary and Extraordinary General Meeting of April 20, 2020

2020-03-26 11:00:00 | Monthly information regarding the total number of voting rights and total number of shares of the Company

2020-03-20 16:15:00 | DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F

2020-03-17 16:00:00 | Monthly information regarding the total number of voting rights and  total number of shares of the Company as of February 29, 2020 and March 4, 2020

2020-03-17 15:00:00 | DBVT Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of DBV Technologies S.A. and Encourages Investors to Contact the Firm

2020-03-17 14:51:54 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

2020-03-17 08:48:35 | The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

2020-03-16 16:30:00 | DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years

2020-03-09 02:58:06 | Did You Manage To Avoid DBV Technologies's EPA:DBV Devastating 77% Share Price Drop?

2020-03-05 11:09:59 | 3 Top Biotech Stocks With Major Catalysts Approaching

2020-03-04 16:30:00 | DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update

2020-03-04 16:01:00 | DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering

2020-03-02 01:30:00 | DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares ADSs

2020-02-24 16:00:00 | DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020

2020-02-21 09:29:00 | DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children

2020-02-10 16:00:00 | DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference

2020-02-06 20:00:00 | Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020

2020-02-06 16:01:00 | DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer

2020-02-04 16:30:00 | DBV Technologies Announces Closing of Global Offering

2020-02-01 15:53:24 | Aimmune's 'First-Of-Its-Kind' Peanut Allergy Drug Receives FDA Approval

2020-01-30 01:30:00 | DBV Technologies Announces Pricing of $153.7 million €139.8 million Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

2020-01-29 16:05:00 | DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position

2020-01-15 16:00:00 | Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

2020-01-14 16:00:00 | Monthly information regarding the total number of voting rights and total number of shares of the Company

2020-01-10 08:18:01 | DBV Technologies is in Overbought Territory: What???s Next?

2020-01-09 08:39:54 | The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

2020-01-08 16:30:00 | DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy

2020-01-02 16:30:00 | DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer

2019-12-17 16:06:47 | Hedge Funds Are Dumping DBV Technologies SA – ADR DBVT

2019-12-10 16:00:00 | Monthly information regarding the total number of voting rights and  total number of shares of the Company

2019-11-19 16:00:00 | Monthly information regarding the total number of voting rights and total number of shares of the Company

2019-11-05 16:30:00 | DBV Technologies to Present at the Stifel 2019 Healthcare Conference

2019-10-30 20:39:59 | Here’s What Hedge Funds Think About DBV Technologies SA – ADR DBVT

2019-10-24 16:01:00 | DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019

2019-10-16 06:30:00 | Monthly information regarding the total number of voting rights and total number of shares of the Company

2019-10-15 16:30:00 | DBV Technologies Announces Closing of Global Offering

2019-10-10 01:30:00 | DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares ADSs

2019-10-09 01:30:00 | DBV Technologies Announces Pricing of $125 million €114 million Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

2019-10-08 16:18:44 | DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position

2019-10-04 11:45:00 | DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy

2019-10-02 16:00:00 | Monthly information regarding the total number of voting rights and total number of shares of the Company

2019-09-19 16:00:00 | Monthly information regarding the total number of voting rights and total number of shares of the Company

2019-09-17 06:28:50 | Does Market Volatility Impact DBV Technologies S.A.'s EPA:DBV Share Price?

2019-09-16 16:19:32 | Analyst: DBV's Peanut Allergy Drug Could Outscore Aimmune's On Safety Front